RNA Editing Platform
Provider 
Founded 2018
Sells To B2B, Enterprise
Pricing Model Licensing, Recurring, Software
Ownership Venture-backed

A programmable RNA editing platform developing therapies for genetic disease.
The RNA editing platform uses programmable technology to make precise edits to RNA, enabling therapeutic correction of genetic disease at the transcript level. It pairs targeting systems with disease-relevant targets.
It supports a pipeline of genetic medicines across multiple therapeutic areas. The approach aims for a durable, tunable therapeutic effect without altering genomic DNA.
| Attribute | RNA Editing Platform | tRNA Therapy Platform | |
|---|---|---|---|
| Provider | |||
| Founded | 2018 | — | |
| Sells To | B2B, Enterprise | — | |
| Pricing Model | Licensing, Recurring, Software | — | |
| Ownership | Venture-backed | Private |
Provider 
Founded 2018
Sells To B2B, Enterprise
Pricing Model Licensing, Recurring, Software
Ownership Venture-backed
Provider 
Founded —
Sells To —
Pricing Model —
Ownership Private


Korro Bio's OPERA platform uses engineered oligonucleotides to make precise RNA edits, co-opting endogenous ADAR to correct disease-causing transcripts.


Ascidian Therapeutics' platform replaces mutated exons at the pre-mRNA level via trans-splicing, without DNA edits or foreign enzymes.


Wave Life Sciences' PRISM platform combines stereopure nucleic acid chemistry with ADAR-recruiting AIMers for therapeutic RNA editing in humans.


Enzymatic RNA manufacturing platform for therapeutic siRNA and related oligonucleotides.


Biomolecular RNA delivery platform targeting specific cells and organs including across the blood-brain barrier.
Korro Bio's OPERA platform uses engineered oligonucleotides to make precise RNA edits, co-opting endogenous ADAR to correct disease-causing transcripts.

Ascidian Therapeutics' platform replaces mutated exons at the pre-mRNA level via trans-splicing, without DNA edits or foreign enzymes.

Wave Life Sciences' PRISM platform combines stereopure nucleic acid chemistry with ADAR-recruiting AIMers for therapeutic RNA editing in humans.

Enzymatic RNA manufacturing platform for therapeutic siRNA and related oligonucleotides.

Biomolecular RNA delivery platform targeting specific cells and organs including across the blood-brain barrier.
